Process Validation with Qualification

Gain a comprehensive understanding of the EU and FDA Process Validation Guidance, how to establish a Process Validation Programme, understand the link between quality by design and process validation, apply relevant tools for process validation including risk assessment

6-7 Mar 2019

& 16-17 Oct 2019

GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 11 Jan

Book now

Course Overview

The two-day process validation in the US and EU, balancing science and risk during the product lifecycle meeting will help you gain an understanding of the EU and FDA process validation guidance, learn how to establish a process validation programme, under the link between Quality by Design and process validation as well as how to apply relevant tools for process validation including risk assessment.

Benefits of attending:

  • Know the scope of the FDA and EU validation guidelines
  • Establish a three-stage, science and risk-based, lifecycle process validation programme
  • Clarify similarities and differences between EU and US expectations
  • Understand how Quality by Design supports process validation
  • Realise significant business benefits from taking a science and risk-based approach

Who should attend

This seminar will be of particular interest to all those from the Pharmaceutical Industry working in:

  • Development
  • Manufacturing
  • Engineering
  • Quality

Personnel from the pharmaceutical and biopharmaceutical industry with the following background:

  • Process engineers
  • Pharmacists
  • Scientists
  • Quality assurance professionals
  • Quality control managers
  • Late-stage product and process development engineers, scientists, pharmacists
  • Technology scale-up and transfer managers
  • Validation and qualification managers
  • Validation and qualification specialists
  • Risk management specialists
  • Lean management specialists
  • Operations managers and engineers

Programme - Day one

The Science and Risk-Based Approach to Process Validation

ICH Q8/9/10/11

Introduction to the FDA Process Validation Guidance

Introduction to the EU Process Validation Guideline and Draft Annex 15

Discussion

Exercise 1: Guidelines

Process Design: FDA Stage 1/EU Pharmaceutical Development

Exercise 2: Process Design

Equipment & Utility Qualification: FDA Stage 2.1/EU Annex 15

Exercise 3: Equipment Qualification

Feedback and Discussion

Process Performance Qualification/Process Validation: FDA Stage 2.2/EU approaches

Programme - Day two

Introduction to Day Two

Quality Risk Management

Exercise 4: Process Validation

Continued Process Validation/Ongoing Process Verification: FDA Stage 3/EU Annex 15

Exercise 5: Ongoing Process Verification

Continual Improvement and Process Optimisation

Exercise 6: Continual Improvement

Feedback and Discussion

Case Study: Process Improvement

Discussion: Implementation Challenges

Case Study: Continued/Ongoing Process Verification

Feedback and Discussion

Presenter

Bruce Davis (6-7 Mar 2019)

Bruce Davis, Senior Consultant, Engineering, QbD and Qualification, Bruce Davis Global Consulting. Bruce is a professional engineer with 20 years’international experience of projects for drug substance and drug product manufacturing facilities. When he was with AstraZeneca, he led major changes to qualification processes globally as well as leading Quality by Design (QbD)cross-functional workshops for newproducts. He is ISPE’s former Chairman and Secretary to ASTM E55.03. For ISPE, he led the QbD case study, now published.

Book now

6-7 Mar 2019
6-7 Mar 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 11 Jan
Enrol now
16-17 Oct 2019
16-17 Oct 2019 Venue not yet confirmed GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • FUJIFILM Diosynth Biotechnologies UK Limited
  • Actelion Pharmaceuticals Ltd
  • Associates of Cape Cod International Inc.
  • AstraZeneca
  • Catalent
  • Chiesi Farmaceutici S.p.a.
  • Cilatus BioPharma Consulting
  • CSL Behring GmbH
  • Cyton Biosciences
  • DCA Design International
  • Dentsply Implants NV
  • ECO Animal Health Group
  • Guerbet
  • Imtool Sarl
  • INION OY
  • Juniper Pharma Services
  • Juniper Pharma Services Ltd
  • LabMinds Ltd
  • Merus NV
  • MHRA
  • ObsEva SA
  • Perrigo API
  • Piramal Pharma Solutions
  • Porton Biopharma LTD
  • Proveris Scientific Corporation
  • Purolite Ltd
  • Reckitt Benckiser
  • Regeneron Pharmaceuticals
  • S T D PHARMACEUTICAL PRODUCTS LTD
  • Semigator GmbH

It is a really interesting course with a lot of valuable information and the speaker has a very good way of presenting the info in effective way

Nancy Almashni, ,

Very informative and engaging. Also valuable the additional inputs with regards to regulatory expectations which may not be apparent just from reading guidances.

Ming Tong, Principal Protein Scientist, Piramal Pharma Solutions

Excellent, will recommend other attend or arrange In-house course

Ian Lafferty, VP Technical Services, Juniper Pharma Services

Very good

Adele Millar, Product Support Officer, Porton Biopharma LTD

Well defined and appropriate discussions governed by industry experts. Great presentation and supporting documents

Andrew Betts, Site Quality Leader, Purolite Ltd

Content very good with lots of examples and exercises to test understanding

Lorraine Wallace, QA Associate Manager, Fujifilm Diosynth Biotechnologies

Content appropriated and excellent speakers

Marta Lopez Garcia, Senior Technical Manager, Bayer Consumer Care AG

The course had aspects that were useful - but the overall content was not really applicable to my role. This was obvious within the first five minutes of the Day 1 when we reviewed objectives. As stated above, maybe this was a misinterpretation of course content

Anna Owens, Quality Assurance Manager, Associates of Cape Cod International Inc